Combining two different immunotherapy treatments could dramatically improve lymphoma survival, according to a Cancer Research UK funded study published in Cancer Cell
Researchers from the University of Southampton tested different combinations of antibodies in the lab to see how they interact with each other and what effect this has on how the immune system fights cancer.
Researchers tested a variety of combinations of ‘tumour targeting’ monoclonal antibodies and ‘immunomodulatory’ monoclonal antibodies. They showed that anti-CD27, an immunomodulatory monoclonal antibody, enhanced anti-CD20 (tumour targeting) therapy in various preclinical models.
They found one combination — anti-CD27 and anti-CD20 – greatly increased life expectancy in mice with cancer. While most of the mice given just one of the antibodies died within 80 days, nearly all mice given both antibodies survived beyond 100 days.
Dr Sean Lim, a Cancer Research UK Clinician Scientist at the University of Southampton, said: “By combining two specific antibodies — anti-CD27 and anti-CD20 — we have increased the ability of the immune system to destroy cancer cells.”
“It is very exciting to see that this drug combination has an impact on survival of mice with lymphoma, as improvements in treatment are urgently needed. The next stage will be to see if what we have discovered can be replicated in patients.”
Median survival for mice given anti-CD20 therapy ranged between 24 and 49 days. Median survival for mice given anti-CD27 therapy ranged between 49 and 79 days. When given the drug in combination, almost all mice survived until they were euthanised at 100 days.
When combined, the researchers found the antibodies recruit greater numbers of immune cells called myeloid cells, as well as increasing their ability to destroy cancer cells.
As a direct result of this study, the combination will now be tested in patients as part of a clinical trial funded by Cancer Research UK. Based on this data, a phase 2, multi centre clinical trial will test the combination of rituximab and varililumab in patients with relapsed and/or refractory B-cell non-Hodgkin’s lymphoma.
Professor Karen Vousden, Cancer Research UK’s Chief Scientist, said: “This study greatly increases our understanding of how different immunotherapies can work together to improve the way we treat lymphoma.”
“By testing this approach in a clinical trial we will see if this promising research will translate into benefit for patients.”